摘要:
The instant invention provides for substituted fused naphthyridine derivatives that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
摘要:
The present invention relates to a compound of Formula (I): wherein: n is 0 or 1; X is O or CH 2 ; R 1 is H or C 1-2 alkyl; R 2 is H or C 1-3 alkyl; R 3 and R 4 are each independently H or C 1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R 10 R 5 is H or OCH 3 ; R 10 is F or Cl; or a pharmaceutically acceptable salt or ester thereof.
摘要翻译:本发明涉及式(I)的化合物:其中:n是0或1; X是O或CH 2; R 1是H或C 1-2烷基; R 2是H或C 1-3烷基; R 3和R 4各自独立地为H或C 1-2烷基,其中所述烷基可被1-3个选自R 10 R 5为H或OCH 3的相同或不同取代基取代; R 10是F或Cl; 或其药学上可接受的盐或酯。
摘要:
The present invention relates to a compound of Formula (I): wherein: R 1 is H or C 1-2 alkyl; R 2 is H or C 1-3 alkyl; R 3 and R 4 are each independently H or C 1-2 alkyl, where the alkyl may be substituted with one to three of the same or different substituents selected from R 10 ; R 5 is H, hydroxy, C 1-2 alkyl, or OCH 3 ; and R 10 is F or Cl, or a pharmaceutically acceptable salt or ester thereof.
摘要:
Disclosed is a compound represented by the general formula [I] below or a pharmaceutically acceptable salt or ester thereof. (I) (In the formula, R1 represents a hydrogen atom, F, CN or the like; R1' represents a hydrogen atom or an optionally substituted lower alkyl group; R2 represents O, S, SO, SO2 or the like;R3 represents an optionally substituted phenyl group; X1, X2 and X3 independently represent CH, N or the like, provided that none or one of X1, X2 and X3 is N; and W represents a group represented by the following formula: , wherein W1, W2 and W3 independently represent CH, N or the like.)